Onxeo, Dara BioSciences deal

Onxeo granted Dara exclusive rights in the U.S. to commercialize Oravig miconazole, which is approved to treat oropharyngeal candidiasis. Additionally, Dara has the right to pursue regulatory approval in Canada, which if granted would give Dara exclusive rights to commercialize the product there. Dara will book revenues and pay Onxeo undisclosed sales milestones. Dara will conduct a pediatric study as part of a postmarketing commitment, which may provide for an expanded indication. ...